Advanced SearchSearch Tips
Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening
Laidi, Fatna; Bouziane, Amal; Errachid, Abdelhamid; Zaoui, Fatima;
  PDF(new window)
Background: The aim of this work was to investigate if serum and salivary auto-antibodies, isotypes IgG and IgM, against HER2 and MUC1 tandem repeat fragments could play a role in breast cancer screening. Materials and Methods: Our case-control study was conducted in breast cancer patients, in early stages (n
Breast cancer;autoantibodies;HER2;MUC1;saliva;serum;
 Cited by
The oral cavity microbiota: between health, oral disease, and cancers of the aerodigestive tract, Canadian Journal of Microbiology, 2017, 63, 6, 475  crossref(new windwow)
Al Kawas S, Rahim ZH, Ferguson DB (2012). Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol, 57, 1-9. crossref(new window)

Arif S, Qudsia S, Urooj S, et al (2014). Blueprint of quartz crystal microbalance biosensor for early detection of breast cancer through salivaryautoantibodies against ATP6AP1. Biosens Bioelectron, 65, 62-70.

Atoum M, Nimer N, Abdeldayem S, et al (2012). Relationships among serum CA15-3 tumor marker, tnm staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 13, 857-60. crossref(new window)

Begum M, Karim S, Malik A, et al (2012). CA 15-3 (mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev, 13, 5257-1. crossref(new window)

Chapman C, Murray A, Chakrabarti J, et al (2007). Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol, 18, 868-3. crossref(new window)

Chapman CJ, Murray A, McElveen JE, et al (2008). Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax, 63, 228-33. crossref(new window)

Desmetz C, Lacombe J, Mange A, et al (2011). Autoanticorps et diagnostic precoce des cancers. Med Sci, 27, 633-8.

Evans RL, Pottala JV, Egland KA (2014). Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prev Res, 7, 545-5. crossref(new window)

Gendler S, Taylor-Papadimitriou J, Duhig T, et al (1988). A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem, 263, 12820-3.

Humphrey SP, Williamson RT (2001). A review of saliva: normal composition, flow, and function. J Prosthet Dent, 85, 162-9. crossref(new window)

Isla Larrain MT, Colussi AG, Demichelis SO, et al (2013). Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients. Int J Biol Markers, 28, 318-5. crossref(new window)

Kufe DW (2013). MUC1-C Oncoprotein as a Target in Breast Cancer; Activation of Signaling Pathways and Therapeutic Approaches. Oncogene, 32, 1073-1. crossref(new window)

Laidi F, Bouziane A, Lakhdar A, et al (2014). Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status. Onco Targets Ther, 7, 1285-9.

Laidi F, Bouziane A, Lakhdar A, et al (2014). Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients. Asian Pac J Cancer Prev, 15, 4659-2. crossref(new window)

Lamster IB, Ahlo JK (2007). Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci, 1098, 216-9. crossref(new window)

Lu H, Ladd J, Feng Z, et al (2012). Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res, 5, 1036-3. crossref(new window)

Maric P, Ozretic P, Levanat S, et al (2011). Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol, 35, 241-7.

Moazzezy N, Farahany T-Z, Oloomi M, et al (2014). Relationship between preoperative serum CA15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev, 15, 1685-8. crossref(new window)

Murphy MA, O'Leary JJ, Cahill DJ (2012). Assessment of the humoral immune response to cancer. J Proteomics, 75, 4573-9. crossref(new window)

Muss HB, Thor AD, Berry DA, et al (1994). c-erbB-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Med, 330, 1260-6. crossref(new window)

Pinkhasov J, Alvarez ML, Rigano MM, et al (2011). Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1. Tg mice. Plant Biotechnol J, 9, 991-1. crossref(new window)

Porika M, Malotu N, Veldandi U-K, et al (2010). Evaluation of tumor markers in Southern Indian breast cancer patients. Asian Pac J Cancer Prev, 11, 157-9.

Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science, 235, 177-2. crossref(new window)

Sotelo MJ, Garcia-Saenz JA, Manso L, et al (2014). Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. J Cancer Res Ther, 10, 967-2. crossref(new window)

Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8. crossref(new window)

Tarhan M-O, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum ca15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9. crossref(new window)

Tarhan Geeraert N, Klausz R, Cockmartin L, et al (2014). Comparison of volumetric breast density estimations from mammography and thorax CT. Phys Med Biol, 59, 4391-9. crossref(new window)

Tjemslanda L and Soreide JA (2004). Operable breast cancer patients with diagnostic delay oncological and emotional characteristics. Eur J Surg Oncol, 30, 721-7. crossref(new window)

Treon SP, Maimonis P, Bua D, et al (2000). Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood, 96, 3147-3.

Tse C (2010). sHER-2: a novel marker? Med Nucl, 34, 66-1.

Wang YQ, Zhang HH, Liu CL, et al (2012). Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer. Asian Pac J Cancer Prev, 13, 5557-2. crossref(new window)

Warnakulasuriya S, Soussi T, Maher R, et al (2000). Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol, 192, 52-7. crossref(new window)

Zhang S-J, Hu Y, Qian H-L, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40. crossref(new window)